(TWST) Twist Bioscience - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US90184D1000
Stock: Synthetic Genes, Oligo Pools, NGS Tools, Antibody Libraries, Viral Controls
Total Rating 29
Risk 33
Buy Signal 0.50
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 67.4% |
| Relative Tail Risk | -6.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.08 |
| Alpha | -41.56 |
| Character TTM | |
|---|---|
| Beta | 1.667 |
| Beta Downside | 1.113 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.97% |
| CAGR/Max DD | 0.30 |
Description: TWST Twist Bioscience January 15, 2026
Twist Bioscience (NASDAQ:TWST) is a U.S.-based synthetic DNA manufacturer that produces custom gene fragments, oligo pools, and related reagents for a broad range of applications, including therapeutics, diagnostics, agricultural biotech, and emerging fields such as DNA data storage and computing.
Its product suite spans synthetic genes for drug discovery, next-generation sequencing (NGS) library kits (exome, custom panels, methylation detection), and specialty controls for viral diagnostics (e.g., SARS-CoV-2, monkeypox). The company also offers antibody-engineering solutions and a strategic partnership with bitBiome to expand its microbial-genomics capabilities.
Key quantitative signals (as of FY 2023) include revenue of roughly $400 million, a gross margin near 70 %, and a cash balance exceeding $300 million, which together provide runway for R&D and capacity expansion. The synthetic DNA market is projected to grow at a CAGR of 12-15 % through 2030, driven by accelerating demand for CRISPR-based therapies and large-scale NGS diagnostics-both of which are core end-markets for Twist.
For a deeper quantitative assessment, consult the ValueRay platform’s detailed TWST valuation model.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -77.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.12 > 0.02 and ΔFCF/TA -0.52 > 1.0 |
| NWC/Revenue: 64.15% < 20% (prev 88.11%; Δ -23.97% < -1%) |
| CFO/TA -0.07 > 3% & CFO -47.6m > Net Income -77.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.4m) vs 12m ago 4.15% < -2% |
| Gross Margin: 50.72% > 18% (prev 0.43%; Δ 5030 % > 0.5%) |
| Asset Turnover: 59.95% > 50% (prev 50.95%; Δ 9.01% > 0%) |
| Interest Coverage Ratio: -459.8 > 6 (EBITDA TTM -52.2m / Interest Expense TTM 167.0k) |
Altman Z'' -13.26
| A: 0.38 (Total Current Assets 333.0m - Total Current Liabilities 91.4m) / Total Assets 641.9m |
| B: -2.06 (Retained Earnings -1.32b / Total Assets 641.9m) |
| C: -0.12 (EBIT TTM -76.8m / Avg Total Assets 628.1m) |
| D: -7.82 (Book Value of Equity -1.32b / Total Liabilities 168.9m) |
| Altman-Z'' Score: -13.26 = D |
Beneish M -2.53
| DSRI: 1.36 (Receivables 57.3m/34.9m, Revenue 376.6m/313.0m) |
| GMI: 0.84 (GM 50.72% / 42.61%) |
| AQI: 1.42 (AQ_t 0.24 / AQ_t-1 0.17) |
| SGI: 1.20 (Revenue 376.6m / 313.0m) |
| TATA: -0.05 (NI -77.7m - CFO -47.6m) / TA 641.9m) |
| Beneish M-Score: -2.53 (Cap -4..+1) = A |
What is the price of TWST shares?
As of February 01, 2026, the stock is trading at USD 41.07 with a total of 1,585,494 shares traded.
Over the past week, the price has changed by -4.35%, over one month by +27.74%, over three months by +31.76% and over the past year by -19.69%.
Over the past week, the price has changed by -4.35%, over one month by +27.74%, over three months by +31.76% and over the past year by -19.69%.
Is TWST a buy, sell or hold?
Twist Bioscience has received a consensus analysts rating of 4.17.
Therefore, it is recommended to buy TWST.
- StrongBuy: 6
- Buy: 3
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the TWST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.5 | 1% |
| Analysts Target Price | 41.5 | 1% |
| ValueRay Target Price | 42 | 2.2% |
TWST Fundamental Data Overview January 31, 2026
P/S = 6.7657
P/B = 5.4426
Revenue TTM = 376.6m USD
EBIT TTM = -76.8m USD
EBITDA TTM = -52.2m USD
Long Term Debt = 75.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 75.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -107.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.39b USD (2.55b + Debt 75.6m - CCE 232.4m)
Interest Coverage Ratio = -459.8 (Ebit TTM -76.8m / Interest Expense TTM 167.0k)
EV/FCF = -31.61x (Enterprise Value 2.39b / FCF TTM -75.6m)
FCF Yield = -3.16% (FCF TTM -75.6m / Enterprise Value 2.39b)
FCF Margin = -20.08% (FCF TTM -75.6m / Revenue TTM 376.6m)
Net Margin = -20.63% (Net Income TTM -77.7m / Revenue TTM 376.6m)
Gross Margin = 50.72% ((Revenue TTM 376.6m - Cost of Revenue TTM 185.6m) / Revenue TTM)
Gross Margin QoQ = 51.35% (prev 53.40%)
Tobins Q-Ratio = 3.72 (Enterprise Value 2.39b / Total Assets 641.9m)
Interest Expense / Debt = 0.19% (Interest Expense 143.0k / Debt 75.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -60.7m (EBIT -76.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.64 (Total Current Assets 333.0m / Total Current Liabilities 91.4m)
Debt / Equity = 0.16 (Debt 75.6m / totalStockholderEquity, last quarter 473.0m)
Debt / EBITDA = 2.06 (negative EBITDA) (Net Debt -107.5m / EBITDA -52.2m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -107.5m / FCF TTM -75.6m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.37% (Net Income -77.7m / Total Assets 641.9m)
RoE = -16.82% (Net Income TTM -77.7m / Total Stockholder Equity 461.8m)
RoCE = -14.29% (EBIT -76.8m / Capital Employed (Equity 461.8m + L.T.Debt 75.6m))
RoIC = -13.14% (negative operating profit) (NOPAT -60.7m / Invested Capital 461.8m)
WACC = 11.72% (E(2.55b)/V(2.62b) * Re(12.06%) + D(75.6m)/V(2.62b) * Rd(0.19%) * (1-Tc(0.21)))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.51%
Fair Price DCF = unknown (Cash Flow -75.6m)
EPS Correlation: 72.20 | EPS CAGR: 41.88% | SUE: 1.57 | # QB: 1
Revenue Correlation: 98.34 | Revenue CAGR: 25.68% | SUE: 1.00 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.47 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-2.47 | Chg30d=-0.710 | Revisions Net=+0 | Growth EPS=-16.8% | Growth Revenue=+14.6%
EPS next Year (2027-09-30): EPS=-2.05 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+17.0% | Growth Revenue=+15.2%
P/B = 5.4426
Revenue TTM = 376.6m USD
EBIT TTM = -76.8m USD
EBITDA TTM = -52.2m USD
Long Term Debt = 75.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 75.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -107.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.39b USD (2.55b + Debt 75.6m - CCE 232.4m)
Interest Coverage Ratio = -459.8 (Ebit TTM -76.8m / Interest Expense TTM 167.0k)
EV/FCF = -31.61x (Enterprise Value 2.39b / FCF TTM -75.6m)
FCF Yield = -3.16% (FCF TTM -75.6m / Enterprise Value 2.39b)
FCF Margin = -20.08% (FCF TTM -75.6m / Revenue TTM 376.6m)
Net Margin = -20.63% (Net Income TTM -77.7m / Revenue TTM 376.6m)
Gross Margin = 50.72% ((Revenue TTM 376.6m - Cost of Revenue TTM 185.6m) / Revenue TTM)
Gross Margin QoQ = 51.35% (prev 53.40%)
Tobins Q-Ratio = 3.72 (Enterprise Value 2.39b / Total Assets 641.9m)
Interest Expense / Debt = 0.19% (Interest Expense 143.0k / Debt 75.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -60.7m (EBIT -76.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.64 (Total Current Assets 333.0m / Total Current Liabilities 91.4m)
Debt / Equity = 0.16 (Debt 75.6m / totalStockholderEquity, last quarter 473.0m)
Debt / EBITDA = 2.06 (negative EBITDA) (Net Debt -107.5m / EBITDA -52.2m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -107.5m / FCF TTM -75.6m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.37% (Net Income -77.7m / Total Assets 641.9m)
RoE = -16.82% (Net Income TTM -77.7m / Total Stockholder Equity 461.8m)
RoCE = -14.29% (EBIT -76.8m / Capital Employed (Equity 461.8m + L.T.Debt 75.6m))
RoIC = -13.14% (negative operating profit) (NOPAT -60.7m / Invested Capital 461.8m)
WACC = 11.72% (E(2.55b)/V(2.62b) * Re(12.06%) + D(75.6m)/V(2.62b) * Rd(0.19%) * (1-Tc(0.21)))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.51%
Fair Price DCF = unknown (Cash Flow -75.6m)
EPS Correlation: 72.20 | EPS CAGR: 41.88% | SUE: 1.57 | # QB: 1
Revenue Correlation: 98.34 | Revenue CAGR: 25.68% | SUE: 1.00 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.47 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-2.47 | Chg30d=-0.710 | Revisions Net=+0 | Growth EPS=-16.8% | Growth Revenue=+14.6%
EPS next Year (2027-09-30): EPS=-2.05 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+17.0% | Growth Revenue=+15.2%